GAITHERSBURG, Md., June 23, 2019 /PRNewswire-PRWeb/ -- Otomagnetics' technology is enabling non-invasive magnetic delivery
The strategic and cost effective engagement between Otomagnetics and Frontage Laboratories is enabling the development of magnetic nanoparticles carrying two drugs for the non-invasive treatment of middle ear infection using Otomagnetics' proprietary magnetic delivery system.
"We are excited about collaborating with a company whose pre-clinical drug development services are exceptional. Engaging with Frontage Laboratories strengthens Otomagnetics' preclinical manufacturing ability, which would facilitate IND enabling studies," says Abhita Batra, CEO of Otomagnetics.
"We are excited to engage Otomagnetics to help manufacture their novel magnetic drug delivery product, which could enable treatment of multiple conditions," says Dr. Song Li, CEO of Frontage Laboratories.
Frontage Laboratories, Inc., is a global full-service Clinical Research Organization with facilities in the US and China. Frontage specializes in research and development (R&D) product development services to pharmaceutical and biotech companies.
Otomagnetics, a Delaware C-Corp and is developing a non-invasive method to deliver drugs and other therapeutic payloads to hard to reach targets in the body, to inner and middle ear compartments, to the eye, and into and through the skin.
Subscribe to our Free Newsletters!